BACKGROUND: Dietary magnesium intake has been favorably associated with reduced risk of metabolic outcomes in observational studies; however, few randomized trials have introduced a systems-biology approach to explore molecular mechanisms of pleiotropic metabolic actions of magnesium supplementation. OBJECTIVE: We examined the effects of oral magnesium supplementation on metabolic biomarkers and global genomic and proteomic profiling in overweight individuals. DESIGN: We undertook this randomized, crossover, pilot trial in 14 healthy, overweight volunteers [body mass index (in kg/m(2)) ≥25] who were randomly assigned to receive magnesium citrate (500 mg elemental Mg/d) or a placebo for 4 wk with a 1-mo washout period. Fasting blood and urine specimens were collected according to standardized protocols. Biochemical assays were conducted on blood specimens. RNA was extracted and subsequently hybridized with the Human Gene ST 1.0 array (Affymetrix, Santa Clara, CA). Urine proteomic profiling was analyzed with the CM10 ProteinChip array (Bio-Rad Laboratories, Hercules, CA). RESULTS: We observed that magnesium treatment significantly decreased fasting C-peptide concentrations (change: -0.4 ng/mL after magnesium treatment compared with +0.05 ng/mL after placebo treatment; P = 0.004) and appeared to decrease fasting insulin concentrations (change: -2.2 μU/mL after magnesium treatment compared with 0.0 μU/mL after placebo treatment; P = 0.25). No consistent patterns were observed across inflammatory biomarkers. Gene expression profiling revealed up-regulation of 24 genes and down-regulation of 36 genes including genes related to metabolic and inflammatory pathways such as C1q and tumor necrosis factor-related protein 9 (C1QTNF9) and pro-platelet basic protein (PPBP). Urine proteomic profiling showed significant differences in the expression amounts of several peptides and proteins after treatment. CONCLUSION:Magnesium supplementation for 4 wk in overweight individuals led to distinct changes in gene expression and proteomic profiling consistent with favorable effects on several metabolic pathways. This trial was registered at clinicaltrials.gov as NCT00737815.
RCT Entities:
BACKGROUND: Dietary magnesium intake has been favorably associated with reduced risk of metabolic outcomes in observational studies; however, few randomized trials have introduced a systems-biology approach to explore molecular mechanisms of pleiotropic metabolic actions of magnesium supplementation. OBJECTIVE: We examined the effects of oral magnesium supplementation on metabolic biomarkers and global genomic and proteomic profiling in overweight individuals. DESIGN: We undertook this randomized, crossover, pilot trial in 14 healthy, overweight volunteers [body mass index (in kg/m(2)) ≥25] who were randomly assigned to receive magnesium citrate (500 mg elemental Mg/d) or a placebo for 4 wk with a 1-mo washout period. Fasting blood and urine specimens were collected according to standardized protocols. Biochemical assays were conducted on blood specimens. RNA was extracted and subsequently hybridized with the Human Gene ST 1.0 array (Affymetrix, Santa Clara, CA). Urine proteomic profiling was analyzed with the CM10 ProteinChip array (Bio-Rad Laboratories, Hercules, CA). RESULTS: We observed that magnesium treatment significantly decreased fasting C-peptide concentrations (change: -0.4 ng/mL after magnesium treatment compared with +0.05 ng/mL after placebo treatment; P = 0.004) and appeared to decrease fasting insulin concentrations (change: -2.2 μU/mL after magnesium treatment compared with 0.0 μU/mL after placebo treatment; P = 0.25). No consistent patterns were observed across inflammatory biomarkers. Gene expression profiling revealed up-regulation of 24 genes and down-regulation of 36 genes including genes related to metabolic and inflammatory pathways such as C1q and tumor necrosis factor-related protein 9 (C1QTNF9) and pro-platelet basic protein (PPBP). Urine proteomic profiling showed significant differences in the expression amounts of several peptides and proteins after treatment. CONCLUSION:Magnesium supplementation for 4 wk in overweight individuals led to distinct changes in gene expression and proteomic profiling consistent with favorable effects on several metabolic pathways. This trial was registered at clinicaltrials.gov as NCT00737815.
Authors: C Malpuech-Brugère; W Nowacki; M Daveau; E Gueux; C Linard; E Rock; J Lebreton; A Mazur; Y Rayssiguier Journal: Biochim Biophys Acta Date: 2000-06-15
Authors: G Paolisso; S Sgambato; A Gambardella; G Pizza; P Tesauro; M Varricchio; F D'Onofrio Journal: Am J Clin Nutr Date: 1992-06 Impact factor: 7.045
Authors: Karl P Schlingmann; Stefanie Weber; Melanie Peters; Lene Niemann Nejsum; Helga Vitzthum; Karin Klingel; Markus Kratz; Elie Haddad; Ellinor Ristoff; Dganit Dinour; Maria Syrrou; Søren Nielsen; Martin Sassen; Siegfried Waldegger; Hannsjörg W Seyberth; Martin Konrad Journal: Nat Genet Date: 2002-05-28 Impact factor: 38.330
Authors: G William Wong; Sarah A Krawczyk; Claire Kitidis-Mitrokostas; Guangtao Ge; Eric Spooner; Christopher Hug; Ruth Gimeno; Harvey F Lodish Journal: FASEB J Date: 2008-09-11 Impact factor: 5.191
Authors: Rebecca B Costello; Ronald J Elin; Andrea Rosanoff; Taylor C Wallace; Fernando Guerrero-Romero; Adela Hruby; Pamela L Lutsey; Forrest H Nielsen; Martha Rodriguez-Moran; Yiqing Song; Linda V Van Horn Journal: Adv Nutr Date: 2016-11-15 Impact factor: 8.701
Authors: Adela Hruby; Julius S Ngwa; Frida Renström; Mary K Wojczynski; Andrea Ganna; Göran Hallmans; Denise K Houston; Paul F Jacques; Stavroula Kanoni; Terho Lehtimäki; Rozenn N Lemaitre; Ani Manichaikul; Kari E North; Ioanna Ntalla; Emily Sonestedt; Toshiko Tanaka; Frank J A van Rooij; Stefania Bandinelli; Luc Djoussé; Efi Grigoriou; Ingegerd Johansson; Kurt K Lohman; James S Pankow; Olli T Raitakari; Ulf Riserus; Mary Yannakoulia; M Carola Zillikens; Neelam Hassanali; Yongmei Liu; Dariush Mozaffarian; Constantina Papoutsakis; Ann-Christine Syvänen; André G Uitterlinden; Jorma Viikari; Christopher J Groves; Albert Hofman; Lars Lind; Mark I McCarthy; Vera Mikkilä; Kenneth Mukamal; Oscar H Franco; Ingrid B Borecki; L Adrienne Cupples; George V Dedoussis; Luigi Ferrucci; Frank B Hu; Erik Ingelsson; Mika Kähönen; W H Linda Kao; Stephen B Kritchevsky; Marju Orho-Melander; Inga Prokopenko; Jerome I Rotter; David S Siscovick; Jacqueline C M Witteman; Paul W Franks; James B Meigs; Nicola M McKeown; Jennifer A Nettleton Journal: J Nutr Date: 2013-01-23 Impact factor: 4.798
Authors: Sally N Adebamowo; Monik C Jiménez; Stephanie E Chiuve; Donna Spiegelman; Walter C Willett; Kathryn M Rexrode Journal: Stroke Date: 2014-08-12 Impact factor: 7.914
Authors: N Veronese; S Watutantrige-Fernando; C Luchini; M Solmi; G Sartore; G Sergi; E Manzato; M Barbagallo; S Maggi; B Stubbs Journal: Eur J Clin Nutr Date: 2016-08-17 Impact factor: 4.016
Authors: Tanguy Corre; Francisco J Arjona; Caroline Hayward; Sonia Youhanna; Jeroen H F de Baaij; Hendrica Belge; Nadine Nägele; Huguette Debaix; Maxime G Blanchard; Michela Traglia; Sarah E Harris; Sheila Ulivi; Rico Rueedi; David Lamparter; Aurélien Macé; Cinzia Sala; Stefania Lenarduzzi; Belen Ponte; Menno Pruijm; Daniel Ackermann; Georg Ehret; Daniela Baptista; Ozren Polasek; Igor Rudan; Toby W Hurd; Nicholas D Hastie; Veronique Vitart; Geràrd Waeber; Zoltán Kutalik; Sven Bergmann; Rosa Vargas-Poussou; Martin Konrad; Paolo Gasparini; Ian J Deary; John M Starr; Daniela Toniolo; Peter Vollenweider; Joost G J Hoenderop; René J M Bindels; Murielle Bochud; Olivier Devuyst Journal: J Am Soc Nephrol Date: 2017-11-01 Impact factor: 10.121